Cited by 42
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma
Gao, Yuanyuan, Mao, Meng, Li, Yue, Xuan, Mingjun, Wu, Yingjie, He, Qiang·2025·Nature Communications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Crossref · 10.1038/s41467-025-60422-z
Cites
2 of 2 references verified0 citation errors · 0 not checkable
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For BBB traversal and deep brain delivery, neutrophil “Trojanbots” encapsulated catalase-powered gelatin nanobots (CatNbots). The assemblies measured about 329 nm (ζ ~ − 35.6 mV), crossed an in vitro BBB with roughly 50% efficiency, and once released self-propelled about 416 μm through GL261 spheroids.”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [64]
In the citing paper
“In orthotopic glioma they increased drug deposition nearly fivefold and extended median survival (median survival 38 days; vs PBS 18 days, EMV@GeNP 25 days, CatNbots 26 days, and NE@EDGNs 34 days) to 45 days without organ toxicity [64] (Fig. 4).”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [64]
In the citing paper
“To clarify comparator context, the source reports BBB penetration of ~ 50% (≈10 × vs GeNPs) and spheroid penetration distance of ~ 416 μm (≈2.8 × vs GeNPs).”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dual-responsive biohybrid neutrobots for active target delivery
Zhang, H., Li, Z., Gao, C., Fan, X., Pang, Y., Li, T., Wu, Z., Xie, H., & He, Q. (2021) · Science Robotics · doi:10.1126/scirobotics.aaz9519 · Cited by 518
Self-citationRyu, Y. S., Kang, K. A., Piao, M. J., Ahn, M. J., Yi, J. M., Bossis, G., Hyun, Y.-M., Park, C. O., & Hyun, J. W. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0305-4 · Cited by 119
Flagged first, then by citations
Research works printed but not linked: 68
- Aldape, K. et al. Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 16, 509–520 (2019). · DOI · Paper page
- Di Mascolo, D. et al. Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours. Nat. Nanotechnol. 16, 820–829 (2021). · DOI
- Weller, M. et al. Glioma. Nat. Rev. Dis. Prim. 10, 33 (2024). · DOI
- Lu, G. H. et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat. Commun. 13, 4214 (2022). · DOI
- Gao, J. J. et al. Precision drug delivery to the central nervous system using engineered nanoparticles. Nat. Rev. Mater. 9, 567–588 (2024). · DOI
- Tang, W. et al. Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem. Soc. Rev. 48, 2967–3014 (2019). · DOI
- Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat. Rev. Cancer 20, 26–41 (2020). · DOI
- Mao, M., Wu, Y. J. & He, Q. Recent advances in targeted drug delivery for the treatment of glioblastoma. Nanoscale 16, 8689–8707 (2024). · DOI
- Gao, C. Y. et al. Biomedical micro-/nanomotors: from overcoming biological barriers to in vivo imaging. Adv. Mater. 33, 2000512 (2021). · DOI
- Wang, X. J. et al. Bioinspired adaptive microdrugs enhance the chemotherapy of malignant glioma: beyond their nanodrugs. Adv. Mater. 36, 2405165 (2024). · DOI
- Chen, S. Q. et al. Enhanced tumour penetration and prolonged circulation in the blood of polyzwitterion-drug conjugates with cell-membrane affinity. Nat. Biomed. Eng. 5, 1019–1037 (2021). · DOI
- Li, S. L., Jiang, P., Jiang, F. L. & Liu, Y. Recent advances in nanomaterial-based nanoplatforms for chemodynamic cancer therapy. Adv. Funct. Mater. 31, 2100243 (2021). · DOI
- Meng, W. R., Hao, Y. Y., He, C. S., Li, L. & Zhu, G. Q. Exosome-orchestrated hypoxic tumor microenvironment. Mol. Cancer 18, 57 (2019). · DOI
- Huang, J. C. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct. Target. Ther. 6, 153 (2021). · DOI · Paper page
- Kim, J. et al. Advanced materials for micro/nanorobotics. Chem. Soc. Rev. 53, 9190–9253 (2024). · DOI
- Zhou, H. J., Mayorga-Martinez, C. C., Pané, S., Zhang, L. & Pumera, M. Magnetically driven micro and nanorobots. Chem. Rev. 121, 4999–5041 (2021). · DOI
- Han, H. et al. Imaging-guided bioresorbable acoustic hydrogel microrobots. Sci. Robot. 9, 3593 (2024). · DOI
- Wu, Z. G., Chen, Y., Mukasa, D., Pak, O. S. & Gao, W. Medical micro/nanorobots in complex media. Chem. Soc. Rev. 49, 8088–8112 (2020). · DOI
- Lu, H. J. et al. A bioinspired multilegged soft millirobot that functions in both dry and wet conditions. Nat. Commun. 9, 3944 (2018). · DOI
- Chen, J. Y. et al. Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation. Nat. Commun. 15, 557 (2024). · DOI
- Wang, S. H. et al. Hydrogen-powered microswimmers for precise and active hydrogen therapy towards acute ischemic stroke. Adv. Funct. Mater. 31, 202009475 (2021).
- Yang, Z. L. et al. Ultrasmall enzyme-powered janus nanomotor working in blood circulation system. ACS Nano 17, 6023–6035 (2023). · DOI
- Simo, C. et al. Urease-powered nanobots for radionuclide bladder cancer therapy. Nat. Nanotechnol. 19, 554–564 (2024). · DOI
- Serra-Casablancas, M. et al. Catalase-powered nanobots for overcoming the mucus barrier. ACS Nano 18, 16701–16714 (2024). · DOI
- Gu, Z. Q. et al. Autonomous nanorobots with powerful thrust under dry solid-contact conditions by photothermal shock. Nat. Commun. 14, 7663 (2023). · DOI
- Villa, K. & Pumera, M. Fuel-free light-driven micro/nanomachines: artificial active matter mimicking nature. Chem. Soc. Rev. 48, 4966–4978 (2019). · DOI
- Ma, Z. C. et al. Femtosecond laser programmed artificial musculoskeletal systems. Nat. Commun. 11, 4536 (2020). · DOI
- Liang, Q. L. et al. The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency. Nat. Biomed. Eng. 3, 729–740 (2019). · DOI
- Gao, C. et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 11, 2622 (2020). · DOI
- Zou, Y. et al. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment. Nat. Commun. 14, 4557 (2023). · DOI
- Gao, C. Y., Zhou, C., Lin, Z. H., Yang, M. C. & He, Q. Surface wettability-directed propulsion of glucose-powered nanoflask motors. ACS Nano 13, 12758–12766 (2019). · DOI
- Fan, R. R. et al. Engineering MMP-2 activated nanoparticles carrying B7-H3 bispecific antibodies for ferroptosis-enhanced glioblastoma immunotherapy. ACS Nano 17, 9126–9139 (2023). · DOI
- Li, Z. X. et al. Biohybrid microrobots regulate colonic cytokines and the epithelium barrier in inflammatory bowel disease. Sci. Robot. 9, eaat2007 (2024). · DOI
- Soto, F., Wang, J., Ahmed, R. & Demirci, U. Medical micro/nanorobots in precision medicine. Adv. Sci. 7, 2002203 (2020). · DOI
- Chen, B. et al. Cell-based micro/nano-robots for biomedical applications: a review. Small 20, 2304607 (2024). · DOI
- Ye, J. M. et al. Biomimetic dual-driven heterojunction nanomotors for targeted catalytic immunotherapy of glioblastoma. Adv. Funct. Mater 35, 2416265 (2024). · DOI
- Sun, J. W., Mathesh, M., Li, W. & Wilson, D. A. Enzyme-powered nanomotors with controlled size for biomedical applications. ACS Nano 13, 10191–10200 (2019). · DOI
- Mathesh, M., Sun, J. W., van der Sandt, F. & Wilson, D. A. Supramolecular nanomotors with “pH taxis” for active drug delivery in the tumor microenvironment. Nanoscale 12, 22495–22501 (2020). · DOI
- Zhang, F. Y. et al. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat. Mater. 21, 1324–1332 (2022). · DOI
- de Avila, B. E. F. et al. Hybrid biomembrane-functionalized nanorobots for concurrent removal of pathogenic bacteria and toxins. Sci. Robot. 3, eaat0485 (2018). · DOI
- Yong, J. L., Mellick, A. S., Whitelock, J., Wang, J. S. & Liang, K. A Biomolecular toolbox for precision nanomotors. Adv. Mater. 35, 2205746 (2023). · DOI
- Xue, J. W. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692–700 (2017). · DOI
- Wu, M. Y. et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat. Commun. 9, 4777 (2018). · DOI
- Chang, Y. et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat. Commun. 14, 2266 (2023). · DOI
- Li, M. et al. Chemotaxis-driven delivery of nano-pathogenoids for complete eradication of tumors post-phototherapy. Nat. Commun. 11, 1126 (2020). · DOI
- Wu, J. F. et al. Dual-responsive nanorobot-based marsupial robotic system for intracranial cross-scale targeting drug delivery. Adv. Mater. 36, 2306876 (2024). · DOI
- Chang, X. W. et al. Enhanced manipulation of tumor microenvironments by nanomotor for synergistic therapy of malignant tumor. Biomaterials 290, 121853 (2022). · DOI
- de Avila, B. E. F. et al. Nanomotor-enabled pH-responsive intracellular delivery of caspase-3: toward rapid cell apoptosis. ACS Nano 11, 5367–5374 (2017). · DOI
- Chen, H. et al. A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma. Nat. Commun. 14, 941 (2023). · DOI
- Gao, C. Y. et al. Stem cell membrane-coated nanogels for highly efficient in vivo tumor targeted drug delivery. Small 12, 4056–4062 (2016). · DOI
- Xuan, M. J., Shao, J. X., Lin, X. K., Dai, L. R. & He, Q. Self-propelled janus mesoporous silica nanomotors with sub-100 nm diameters for drug encapsulation and delivery. Chemphyschem 15, 2255–2260 (2014). · DOI
- Shao, J. X. et al. Chemotaxis-guided hybrid neutrophil micromotors for targeted drug transport. Angew. Chem.-Int. Ed. 56, 12935–12939 (2017). · DOI
- Michael, M. & Vermeren, S. A neutrophil-centric view of chemotaxis. Essays Biochem. 63, 607–618 (2019). · DOI
- Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013). · DOI · Paper page
- de Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378–391 (2016). · DOI · Paper page
- Howse, J. R. et al. Self-motile colloidal particles: from directed propulsion to random walk. Phys. Rev. Lett. 99, 048102 (2007). · DOI
- Li, J. W. et al. Water-soluble and degradable gelatin/polyaniline assemblies with a high photothermal conversion efficiency for ph-switchable precise photothermal therapy. ACS Appl. Mater. Interfaces 14, 52670–52683 (2022). · DOI
- Helms, H. C. et al. In vitro models of the blood-brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J. Cereb. Blood Flow. Metab. 36, 862–890 (2016). · DOI · Paper page
- Hyun, Y. M., Choe, Y. H., Park, S. A. & Kim, M. LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) distinctly regulate neutrophil extravasation through hotspots I and II. Exp. Mol. Med. 51, 1–13 (2019). · DOI
- Chauhan, V. P. & Jain, R. K. Strategies for advancing cancer nanomedicine. Nat. Mater. 12, 958–962 (2013). · DOI
- Cho, Y. & Doh, J. The extracellular matrix in solid tumor immunotherapy. Trends Immunol. 45, 705–714 (2024). · DOI
- Zhou, C. et al. Torque-driven orientation motion of chemotactic colloidal motors. Angew. Chem.-Int. Ed. 61, e202116013 (2022). · DOI
- Yan, Y. L. et al. Suppression of ITPKB degradation by Trim25 confers TMZ resistance in glioblastoma through ROS homeostasis. Signal Transduct. Target. Ther. 9, 58 (2024). · DOI
- Zaher, A., Petronek, M. S., Allen, B. G. & Mapuskar, K. A. Balanced duality: H2O2-based therapy in cancer and its protective effects on non-malignant tissues. Int. J. Mol. Sci. 25, 8885 (2024). · DOI
- Wang, H. et al. Synergistic chemoimmunotherapy augmentation via sequential nanocomposite hydrogel-mediated reprogramming of cancer-associated fibroblasts in osteosarcoma. Adv. Mater. 36, 2309591 (2024). · DOI
- Robins, E. et al. Conversion of effector CD4+ T cells to a CD8+ MHC II-recognizing lineage. Cell. Mol. Immunol. 18, 150–161 (2021). · DOI
- Hameedat, F. et al. Engineering nanomaterials for glioblastoma nanovaccination. Nat. Rev. Mater. 9, 628–642 (2024). · DOI
- Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016). · DOI · Paper page
Cited by
Sorted by citations
Sheng, J., Yuan, W., Zhang, M., Chen, Z., Qi, Y., Zhao, Y., & Zhang, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04028-7 · Cited by 35
Metadata
- Authors
- Gao, Y., Mao, M., Li, Y., Xuan, M., Wu, Y., & He, Q.
- Venue
- Nature Communications
- Published
- 2025-06-06
- Volume
- 16
- Issue
- 1
- ISSN
- 2041-1723
- PMC
- PMC12144173
- Cited by
- 42
- References
- 2
- Language
- en
- Licence
- Funders
- National Natural Science Foundation of China (22193033, U23A20342)
- the Key R&D Program of Heilongjiang Province, China
- China Postdoctoral Science Foundation (2024M764205)
- the Postdoctoral Fellowship Program of CPSF
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
